Centre National De La Recherche Scientifique

Elro Pharma Sarl

Universite Paris 12 - Val De Marne

Université Pierre Et Marie Curie

Université Paris Est Creteil Val De Marne

Elro Pharma

José Courty

Gilles Guichard

Denis S Barritault

Ara G Hovanessian

Robert H Zimmer

Jean Paul Briand

Ali Ladram

Robert Zimmer

Yamina Hamma

Annie Lang

Isabelle Pierrot

Jean Delbe

Pierre Milhiet

Chantal Devin

Mohamed Amiche

Pierre Nicolas

Cécile Galanth

Denis Barritault

Johanna Allegonda Anna Van Zoggel

Ara Hovanessian

Haixing Zhang

The present invention relates to a composition comprising a Nucant multivalent synthetic compound and a glycosaminoglycan, the admixture of both compounds forming microspheres comprising both compounds, as well as their use for the treatment or prevention of diseases associated with deregulation of proliferation and/or angiogenesis, such as cancer, inflammatory disease, or for promoting wound healing.

Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans

A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I).

Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation

The invention concerns peptide fragments 13-39 and 65-97 of the HARP factor, which inhibit angiogenesis. Advantageously, said peptides can be associated with the peptide 111-136 of HARP. The invention also concerns pharmaceutical compositions comprising said peptides or nucleic acids encoding said peptides, and their use for treating pathologies associated with an angiogenesis, in particular proliferative disorders such as cancer.

Peptide fragments of the harp factor inhibiting angiogenesis

Growing community of inventors

Villecresnes, France

José Courty